This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
News|Articles|January 27, 2005
Warning Letter
FDA cites Essential Pharmacy Compounding (Omaha) for bulk-compounding of verterinary drugs.
Advertisement
The warning cited large-scale compounding of altrenogest, amikacin sulfate, dipyrone, flunixin belumine, ketoprofen, ivermectin, ompeprazole, phenylbutazone, and tripelemine hydrochoride, "among many others." As is typical in these warnings, the agency voiced concerns that Essential is compounding not for individual patients but for third-party resale, and that the compounded drugs duplicate approved products in dosage and concentration.
Advertisement
Related to this article
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
The agency issued a direct final rule that supports the use of innovative testing methods to limit the use of animals and maintain existing safety standards.
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
Advertisement
Advertisement